Summary
Project B03 will apply multi-modal proteomics to understand and overcome adaptive drug-resistance mechanisms in FLT3-mutated AML. Using primary AML cells, PDX and cell line models, and CRISPR-based screens, drug screens, RNAseq and proteomic approaches B03 will decipher how plasticity of FLT3-mutated AML cells leads to TKI-resistance, and will identify novel vulnerabilities in TKI-resistant cells.
principal Investigator
Jeroen Krijgsveld, Prof. Dr.
Excellence Cluster Cell Networks, Medical Faculty, Heidelberg University
principal Investigator
Maximilian Felix Blank, Dr. med.
Department of Hematology Oncology, Heidelberg University Hospital
Team:
Cell-Extrinsic Factors (Area B)
Our consortium of scientists, clinicians and partners
Alexander Wahl
PhD student
Jeroen Krijgsveld, Prof. Dr.
Principal Investigator
Maximilian Felix Blank, Dr. med.
Principal Investigator
